DNMT inhibitors such as RG108, N-acetylcysteine, and 5-aza-2′-deoxycytidine restore hypermethylation in endothelial cells, but their clinical applications for treating atherosclerosis are pending U.S. Food and Drug Administration (FDA) approval [50]. The gene discussed is DNMT1; the disease is atherosclerosis.